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MSX2, a member of the homeobox genes family, is demonstrated to be the downstream
target for ras signaling pathway and is expressed in a variety of carcinoma cells,
suggesting its relevance to the development of ductal pancreatic tumors since pancreatic
ductal adenocarcinoma (PDAC) and intraductal papillary-mucinous neoplasia (IPMN) harbor
frequent K-ras gene mutations. Recent studies revealed the roles of MSX2 in the
development of carcinoma of various origins including pancreas. Among gastrointestinal
tumors, PDAC is one of the most malignant. PDAC progresses rapidly to develop
metastatic lesions, frequently by the time of diagnosis, and these tumors are usually
resistant to conventional chemotherapy and radiation therapy. The molecular mechanisms
regulating the aggressive behavior of PDAC still remain to be clarified. On the other hand,
IPMN of the pancreas is distinct from PDAC because of its intraductal growth in the
main pancreatic duct or secondary branches with rare invasion and metastasis to distant
organs. However, recent evidence indicated that once IPMN showed stromal invasion,
it progresses like PDAC. Therefore, it is important to determin how IPMN progresses
to malignant phenotype. In this review, we focus on the involvement of MSX2 in the
enhancement of malignant behavior in PDAC and IPMN, and further highlight the clinical
approach to differentiate PDAC from chronic pancreatitis by evaluating MSX2 expression
level.
Keywords: pancreatic ductal adenocarcinoma, intraductal papillary-mucinous neoplasm of the pancreas, cancer
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INTRODUCTION
Homeobox-containing genes regulate the morphological devel-
opment of a variety of organs and their expression levels vary
according to the development stages of organ (Wolgemuth et al.,
1989; Morgan et al., 1992). The expression of MSX2, a member
of the homeobox gene (Hox gene) family, is observed in a variety
of sites, including premigratory cranial neural crest, tooth, and
mammary gland, etc (Takahashi and Le Douarin, 1990; Davidson
et al., 1991; Monaghan et al., 1991; Jowett et al., 1993; Davidson,
1995; Friedmann and Daniel, 1996; Phippard et al., 1996). The
expression pattern of this gene in the development of organs
suggests its pivotal role in epithelial–mesenchymal interactions
(Satoh et al., 2004). On the other hand, accumulating evidence
Abbreviations: PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal
papillary-mucinous neoplasia; MD-IPMN, main duct type intraductal papillary-
mucinous neoplasia; BD-IPMN, branch duct type intraductal papillary-mucinous
neoplasia; HPDE, human normal pancreatic duct epithelial cell line; PSC, pan-
creatic stellate cells; RT-PCR, reverse transcription-polymerase chain reaction;
siRNA, small interfering RNA; shRNA, small hairpin RNA; BrdU, 5-bromo-2-
deoxyuridine; BMP4, Bonemorphogenetic protein 4; EMT, epithelial to mesenchy-
mal transition; QRT-PCR, quantitative real-time reverse transcription-polymerase
chain reaction; CSC, cancer stem cell; SP, side population; CP, chronic pancreatitis;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
has revealed the active involvement of this gene in tumorige-
nesis and/or tumor development. MSX2 has been suggested to
be a downstream target of the Ras signaling pathway because
MSX2 was up-regulated in v-Ki-ras transfected NIH3T3 cells
and antisense MSX2 cDNA and truncated MSX2 cDNA inter-
fered with the transforming activities of both the v-K-ras and
v-raf oncogene (Takahashi et al., 1996). In addition, the enhanced
expression of MSX2 has been shown in a variety of carcinoma cell
lines of epithelial origin compared to their corresponding normal
tissues (Suzuki et al., 1993). In gastric cancer, MSX2 was identi-
fied as a cancer- specific hedgehog target and the down-regulation
of this gene resulted in the inhibition of cancer cell growth in vitro
(Ohta et al., 2009). Similarly,MSX2 has been shown to be a down-
stream target of WNT signal and has been correlated with the
invasiveness of endometrioid adenocarcinoma (Zhai et al., 2011).
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most malignant gastrointestinal tumors. Once PDAC is clini-
cally evident, it progresses rapidly to develop metastatic lesions,
frequently by the time of diagnosis. Moreover, this carcinoma
usually shows resistance to conventional chemotherapy and radi-
ation therapy. Although recent molecular analyses of precursor
lesions revealed an association between gene alterations and car-
cinogenesis (Hong et al., 2011), the pathogenic mechanisms that
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regulate the aggressive behavior of this cancer still remain to
be clarified. On the other hand, intraductal papillary-mucinous
neoplasia (IPMN) of the pancreas is a unique neoplasm that is
considered to be a precancerous lesion analogous to adenoma-
tous polyps of the colon (Loftus et al., 1996). IPMNs are classified
as main duct type (MD-IPMN) or branch duct type (BD-IPMN)
based on the location of the main tumor, detected by imaging
studies or histology. BD-IPMN is likely to have a less aggressive
biological behavior than MD-IPMN (Kobari et al., 1999; Terris
et al., 2000; Doi et al., 2002; Hara et al., 2002; Kitagawa et al.,
2003;Matsumoto et al., 2003; Sugiyama et al., 2003). However, the
activation of oncogenes such as K-ras (Satoh et al., 1996), sonic
hedgehog (Satoh et al., 2008b), and c-erb B-2 (Satoh et al., 1993a),
accumulation of p53 (Satoh et al., 1996), or the expression of a
member of inhibitor of apoptosis family, survivin, (Satoh et al.,
2001) as well as loss of chromosome 18q (Fukushige et al., 1998)
in BD-IPMN, indicate the malignant potential of this neoplasm.
Furthermore, stromal infiltration and distal metastasis have been
reported even in this type of tumor (Sugiyama et al., 1998; Yasuda
et al., 1998).
Until recently there has been little information about the
expression or function of MSX2 in pancreatic tumors, although
both PDAC and IPMN harbor frequent K-ras gene mutations at
codon 12 (Satoh et al., 1993b, 1996) and MSX2 was suggested to
be a downstream target of the ras signal. In this review, we sum-
marize the recently identified roles and functions of MSX2 in the
development of pancreatic tumors (PDAC and IPMN). We also
demonstrate the validity of measuring the MSX2 expression level
in clinical samples for the diagnosis of PDAC.
EXPRESSION OF MSX2 IN PANCREATIC TISSUE
MSX2 was shown to be expressed in the expanding epithelia of
the fetal murine pancreas, where PDX-1 was also detected, but
not in the duct of the adult murine pancreas, suggesting that
MSX2 might play a role in regulating the pancreatic develop-
mental program (Kritzik et al., 1999). In cultured human cell
lines, MSX2 expression was found in pancreatic cancer cell lines
while it was not observed in human normal pancreatic duct
epithelial cell line (HPDE) nor in pancreatic stellate cells (PSC)
(Table 1) (Satoh et al., 2008a, 2010, 2011). Reverse transcription-
polymerase chain reaction (RT-PCR) analysis of microdissected
lesions also revealed that MSX2 expression occurred only in
tumor lesions including carcinoma cells in PDAC tissues, and
borderline to carcinoma cells in IPMN tissues, while no and
Table 1 | Relative expression of MSX2 in cultured pancreatic cells
(Satoh et al., 2008a, 2010).
Cell Relative MSX2
expression
Panc-1 1
AsPC-1 0.87
MIAPaca2 0.3
BxPC3 0.02
Pancreatic stellate cell 0.01
Human pancreatic epithelial cell (HPDE) <0.001
faint expression of MSX2 transcripts was found in normal duct
and adenoma cells of IPMN, respectively. The dominant MSX2
expression in cancer cells was also reported in other carcinomas
such as bile duct (Ito et al., 2011), stomach (Ohta et al., 2009),
and breast (Di Bari et al., 2009). Consistent with these findings,
MSX2 expression is likely to be restricted to neoplastic duct cells
in adult human pancreas.
The correlation between the up-regulation of MSX2 and clin-
icopathological factors was investigated in a number of carci-
nomas. The expression of this gene was associated with good
prognosis in breast carcinoma (Lanigan et al., 2010) and malig-
nant melanoma (Gremel et al., 2011), while this gene expression
was increased significantly in tumors with metastasis compared
to those without metastasis in prostate carcinoma (Chua et al.,
2010). In human PDAC tissues, frequentMSX2 expression in can-
cer cells was observed by immunohistochemistry and a significant
correlation was found between MSX2 expression and histologi-
cal differentiation and vascular invasion, whereas there was no
association between this gene expression and the tumor stage
(Table 2) (Satoh et al., 2008a), suggesting that MSX2 expression
may be associated with the aggressiveness of PDAC because poor
differentiation of PDAC is correlated with reduced survival time
(Cleary et al., 2004).
THE EFFECT OF MSX2 ON GROWTH OF PANCREATIC
CARCINOMA AND NORMAL EPITHELIAL DUCT CELLS
It has been suggested that MSX2 may induce the proliferation of
osteoprogenitors (Dodig et al., 1999), as well as osteoblasts (Liu
et al., 1999), and this was gene also related to the enhancement of
branchingmorphogenesis inmousemammary ducts (Satoh et al.,
2007). In addition, knockdownofMSX2 by small interfering RNA
(siRNA) or small hairpin RNA (shRNA) inhibited the cell growth
of gastric (Ohta et al., 2009) and ovarian (Zhai et al., 2011) carci-
noma, indicating that the function ofMSX2 is likely to be relevant
to the regulation of the proliferation of epithelial cells as well as
Table 2 | Correlation between clinicopathologic findings and MSX2
expression (Satoh et al., 2008a).
MSX2<30% ≥30% P-value*
Stage 0.957
I 1 2
II 1 1
III 4 4
IV 8 11
Histological classification 0.004
Well differentiated 8 2
Moderately differentiated 6 9
Poorly differentiated 0 7
Vascular invasion <0.0001
v0 0 3
v1 6 1
v2 8 1
v3 0 12
*Chi-square analysis.
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osteogenic cells. The involvement of MSX2 in normal pancre-
atic duct cell growth was examined using HPDE cells retrovirally
transfected withMSX2 (Satoh et al., 2010). The effect ofMSX2 on
cell growth was analyzed by cell count every 48 h after seeding the
cells. HPDE cells transfected with MSX2 demonstrated approx-
imately 2.5-fold more cells compared to HPDE control cells at
4 days after seeding these cells. Similarly, forced expression of
MSX2 in BxPC3 resulted in a significant induction of prolifera-
tion after 72 h of culture compared to control cells as determined
by 5-bromo-2-deoxyuridine (BrdU) assay (Satoh et al., 2008a). In
addition, MSX2 down-regulated Panc-1 cells by shRNA transfec-
tion significantly reduced the cellular growth rate. These findings
clearly indicate that MSX2 facilitate the cellular growth of both
benign and malignant pancreatic duct cells.
MSX2 AND INVASION OR METASTASIS OF PDAC
Bone morphogenetic protein 4 (BMP4) has been shown to induce
epithelial to mesenchymal transition (EMT) in PDAC cells and
that MSX2 is indispensable for this phenomenon (Hamada et al.,
2007). This raised the question of whether MSX2 itself could
cause the EMT of PDAC cells. The involvement of this gene
in the EMT of PDAC was investigated using MSX2 up- and
down-regulated PDAC cells in gain and loss of function man-
ners, respectively. As endogenous MSX2 expression was low in
BxPC3 and high in Panc-1 cells (Table 1), several clones of BxPC3
stably overexpressing MSX2 and Panc-1 stably expressing MSX2
shRNA were generated (Satoh et al., 2008a). A significant mor-
phological difference was observed between MSX2-transfected
and control cells (parental BxPC3 and empty vector transfected
cells). MSX2-expressing cells showed loose cell junctions, scat-
tered morphology, and a more fibroblast-like appearance com-
pared to control cells. A similar morphological change was
observed between MSX2 expressing and down-regulated Panc-1
cells. MSX2 expressing parental Panc-1 and empty-vector trans-
fected cells showed loose cell junctions and scattered morphol-
ogy, while the MSX2 down-regulated cell lines demonstrated
a cobblestone-like phenotype. By immunofluorescent staining,
BxPC3 cells transfected with MSX2 exhibited a weakly diffuse
distribution of E-cadherin and β-catenin in the cytoplasm, while
control cells showed dominant membrane-bound staining. These
molecular changes in MSX2 expressing cells are consistent with
EMT. Consistent with the morphological and molecular changes,
MSX2-expressing pancreatic cancer cells showed enhanced cell
migration by wound healing scratch assay and two-chamber
assay, while down-regulation of MSX2 in Panc-1 is associated
with the suppression of cell migration. This evidence clearly
indicates that MSX2 itself plays a crucial role in the EMT of
PDAC cells (Satoh et al., 2008a). The effect of MSX2 on EMT
was also investigated in mammary and ovarian cells. MSX2
transfected NMuMG cell, a spontaneously immortalized nor-
mal mouse mammary epithelial cell line, showed morphological
and molecular changes consistent with EMT (Di Bari et al.,
2009). MSX2-expressing NMuMG cells appeared spindle-shaped
or fibroblast-like in the monolayer culture and showed reduced
expression of the epithelial marker E-cadherin concomitant with
the increased expression of mesenchymal markers vimentin and
N-cadherin. In addition, forced expression of MSX2 in NMuMG
cells resulted in the promotion of invasiveness. On the other hand,
Zhai et al. demonstrated that ectopic expression of MSX2 also
enhanced the invasiveness of ovarian carcinoma cells in vivo (Zhai
et al., 2011). Since the expression of MSX2 in selected ovarian
carcinoma cells induced changes suggestive of EMT but MSX2
expression was not consistently correlated with EMT markers in
primary tumor specimens, they speculated that the involvement
ofMSX2 in EMTwas complex and context-dependent. Therefore,
although the involvement of MSX2 in tumor invasion was consis-
tently observed in several kinds of carcinoma, the role of MSX2 in
EMT might depend on the tumor species.
MSX2 expression also promoted cell migration or metastasis
formation in an orthotopic environment. Control cells, MSX2
expressing cells and shMSX2 cells were injected into the pan-
creas of nude mice. Tumors were observed in the pancreas of mice
implanted with all MSX2-expressing or shRNA-transfected MSX2
cells and control cells. MSX2-expressing cells frequently showed
metastases to the liver and peritoneal dissemination, while con-
trol cells demonstrated no liver metastasis or only one peritoneal
invasion (Table 3). By contrast, the metastases to the liver and
peritoneal dissemination were suppressed in the mice injected
with MSX2-inactivated cells (Table 3). In this context, MSX2 is
likely to facilitate PDACmetastasis through the induction of EMT.
The mechanisms underlying the induction of EMT by MSX2
in PDAC cells were assessed by cDNA microarray, which identi-
fied the differentially expressed genes between control and MSX2
expressing cells (National Center for Biotechnology Information
Gene Expression Omnibus database, GSE6585). Among the genes
significantly up-regulated by MSX2, Twist1 was one of the most
strongly induced genes in MSX2-expressing cells compared to
control cells. Twist 1 was initially identified as a crucial regulator
of embryonic morphogenesis in Drosophilia (Yang et al., 2004). A
recent study revealed that Twist 1 is involved in invasion and/or
metastasis through the induction of EMT in various types of
carcinoma cells (Mironchik et al., 2005). In PDAC, immunohis-
tochemical analysis showed that Twist 1 expression was correlated
with MSX2 expression and the colocalization of these proteins
was confirmed by double staining of fluorescence immunohisto-
chemistry. In addition, nuclear expression of Twist 1 disappeared
when MSX2 was down-regulated in Panc-1 cells (Satoh et al.,
2008a). These findings suggest that MSX2 is likely to function
in leading the PDAC cells to the state of EMT through the
up-regulation of Twist 1.
Table 3 | Summary of orthotopic implantation of MSX2-expressing or
down-regulated cells in nude mice (Satoh et al., 2008a).
Metastasis Peritoneal
to liver dissemination
BxPC3 control# (n = 5) 0 1
MSX2 expressing BxPC3 (n = 5) 3* 5*
Panc-1 control# (n = 5) 4* 3*
MSX2 down-regulated Panc-1 (n = 5) 0 0
#Control cells were transfected with empty vector; *P < 0.05 (Chi-square
analysis).
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THE ROLE OF MSX2 IN THE DEVELOPMENT OF IPMN
IPMN is distinct from PDAC because it grows slowly and is
rarely invasive, resulting in a better prognosis compared to PDAC
(Loftus et al., 1996). However, recent evidence has indicated that
once IPMN demonstrates stromal invasion, it progresses like
PDAC (Sugiyama et al., 1998; Yasuda et al., 1998). Therefore, it
is important to know how IPMN attains malignant phenotype.
MSX2 is expressed in PDAC and its expression enhanced the
aggressiveness of PDAC cells through the induction of EMT, as
described above, and this gene is suggested to be a downstream
target for ras signal (Takahashi et al., 1996). Since IPMN, like
PDAC, harbors frequent K-ras mutations (Satoh et al., 1993b,
1996), the association of MSX2 expression with the tumor grade
or clinicopathological features was examined in IPMN tissues to
determine whether this gene could be involved in the process of
benign-to-malignant progression in IPMN (Satoh et al., 2010).
The expression levels of MSX2 mRNA in microdissected lesions
from IPMNs were investigated by one-step quantitative real-time
RT-PCR (QRT-PCR). The expression levels of MSX2mRNAwere
increased in a stepwise manner from benign to malignant IPMN.
Carcinoma lesions of IPMN expressed significantly higher lev-
els of MSX2 mRNA than adenoma and borderline of IPMN
cells did, while no significant difference was found between non-
tumor lesions and adenoma-borderline IPMN cells. Consistent
with the results of QRT-PCR, the immunoreactivity of MSX2
was frequently found in borderline IPMN (3/5, 60%), carcinoma
of IPMN (12/19, 63.2%), and invasive carcinoma derived from
IPMN (5/5, 100%), while its expression was seen in only one of
16 adenoma of IPMN tissues. When multivariate analysis among
seven clinical parameters, including age, sex, branch duct size,
nodule size, diameter of main pancreatic duct, serum CEA and
CA19-9 levels, in addition to MSX2 expression, was done, MSX2
expression was identified as the only independent factor that
predicted malignant BD-IPMN (Table 4).
A branch duct size cutoff of 30mm has been widely accepted
as a factor for predicting the malignancy of BD-IPMN (Tanaka
et al., 2006). However, its low sensitivity for malignancy has also
been reported (Pelaez-Luna et al., 2007). Thus, more specific
predictive factors for malignant BD-IPMN were explored by var-
ious approaches. Clinical findings such as branch size, presence
of nodule or dilatation of the main pancreatic duct have been
described as signs of malignant BD-IPMN (Kitagawa et al., 2003;
Sugiyama et al., 2003; Kobayashi et al., 2005; Pelaez-Luna et al.,
2007). Similarly, molecular events including mutation of K-ras
(Satoh et al., 1993b, 1996), inactivation of p53 (Satoh et al., 1996)
or smad4 (Biankin et al., 2002) were demonstrated to be corre-
lated with malignant BD-IPMN. However, it is known whether
molecular markers would be better predictive factors for malig-
nant BD-IPMN than clinical parameters such as nodule size or
dilatation of a branch duct. Based on the above findings, MSX2
expression was found to be a better predictive factor for carci-
noma of IPMN compared to the clinical parameters that were
previously reported to be relevant to malignant IPMN.
MSX2 AND CHEMORESISTANCE OF PDAC
Carcinoma tissues are known to consist of a heterogeneous cel-
lular population containing a minor population of permanent
Table 4 | Predictive factors for malignant IPMN by multivariate
analysis (Satoh et al., 2010).
Parameter Adjusted odds ratio
(confidence interval)
Age (≥70) 0.38 (0.06 – 2.35)
Sex 0.51 (0.08 – 3.28)
Branch (≥30mm) 2.90 (0.46 – 18.26)
Main pancreatic duct (≥6mm) 2.01 (0.24 – 16.65)
Nodule (≥6mm) 2.99 (0.39 – 22.65)
CEA (>5) 0.65 (0.08 – 5.22)
CA19-9 (>37) 6.91 (0.12 – 394.4)
MSX2 expression 8.19 (1.4 – 47.9)*
*P < 0.02 (Log rank regression analysis).
proliferating cells and a major population of differentiated cells
with limited proliferation potential. Among the permanent pro-
liferating cells, so-called cancer stem cells (CSCs) are considered
to be responsible for the initiation, metastasis, chemoresistance
and recurrence of tumor (Reya et al., 2001). Recently, the induc-
tion of a breast CSC phenotype by the forced expression of Snail
and Twist, which leads to EMT, has been demonstrated (Mani
et al., 2008). Since increased expression of MSX2 induced EMT
and enhanced the metastasis of PDAC cells, MSX2 is likely to
have pivotal role in maintaining the characteristics of CSCs. Thus,
the involvement of MSX2 in chemoresistance, which is one of the
characteristics of CSCs in PDAC, was investigated (Hamada et al.,
2012). To assess the association between MSX2 and chemore-
sistance, MSX2-expressing and down-regulated PDAC cells were
treated with gemcitabine or 5-FU. The survival of MSX2 express-
ing PDAC cells was approximately twofold greater than that of
control cells, while MSX2 down-regulated cells showed 30–50%
decreases in cell viabilities after gemcitabine or 5-FU treatment.
Furthermore, forced or reduced expression of MSX2 in PDAC
gave rise to increased or decreased numbers of side popula-
tion (SP) cells, which have been shown to be associated with
CSCs (Dean et al., 2005; Golebiewska et al., 2011), respec-
tively. Interestingly, the chemoresistance of PDAC cells by MSX2
expression was abolished when ATP-binding cassette transporter
ABCG2, identified as one of the MSX2 target genes by cDNA
microarray as described above, was down-regulated by siRNA
transfection. Based on these findings, it is suggested that MSX2
enhances the chemoresistance through ABCG2 induction and the
increase in the CSC phenotype.
CLINICAL APPLICATION FOR DIAGNOSIS OF PDAC BY
MEASURING MSX2 EXPRESSION LEVEL
Endoscopic pancreatic duct brushing is a convenient diagnos-
tic method for strictures in the main pancreatic duct or in
the second branch. However, the diagnostic sensitivity of this
method for PDAC is shown to be low (40–70%) (McGuire et al.,
1996; Vandervoort et al., 1999; Pugliese et al., 2001; Uchida
et al., 2007). Since MSX2 expression is limited to neoplastic
duct cells in the adult pancreas, the detection of MSX2 could
be a useful marker for the diagnosis of PDAC. Therefore, the
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expression level of MSX2 mRNA was investigated in 95 endo-
scopic brushing samples from stricture of the pancreatic duct
to determine whether MSX2 expression could distinguish malig-
nant from benign pancreatic diseases and improve the diagnostic
yield of brush cytology (Satoh et al., 2011). The samples were
collected when ductal strictures were found during ERCP using
cytology brushes with 0.025–0.035 inch guide wire. QRT-PCR
was carried out on each sample by adding the same amount of
total RNA.
In 13 of 95 patients (13.7%), cytological brushing could not
be done because the guide wire could not be passed through the
ductal stricture. In the remaining 82 patients, endoscopic brush-
ing was successfully carried out and satisfactory specimens were
obtained from all cases. Final diagnoses were PDAC (n = 57)
and chronic pancreatitis (CP, n = 25). The sensitivity of routine
brush cytology for PDAC was 47.4% (27/57) with 100% speci-
ficity and 63.4% diagnostic accuracy (Table 5). MSX2 mRNAs
in brushing samples were successfully detected and quantified
Table 5 | Comparison between cytology and MSX2 measurement in
brush samples (Satoh et al., 2011).
Sensitivity (%) Specificity (%) Accuracy (%)
Cytology 47.4 100 63.4
MSX2 evaluation 73.7 84.0 79.3
Table 6 | MSX2 expression levels in ERCP brush samples (Satoh et al.,
2011).
Number of Mean MSX2 P-value#
samples expression level*
PDAC 57 0.012±0.0024 <0.0001
CP 25 0.0026±0.0004 −
*MSX2/GAPDH (copy number/µl, mean ± standard error).
#Mann–Whitney U-test.
by normalization to the respective glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) copy number. The mean expression
level of MSX2 mRNA was significant higher in PDAC sam-
ples than benign strictures (Table 6). The MSX2 expression level
was judged positive when it was equal to or higher than the
cut-off value which was defined by the receiver operating char-
acteristic curve. Using this cut-off value, the sensitivity, speci-
ficity for malignancy, and accuracy for diagnosis were 73.7, 84.0,
and 79.3%, respectively (Table 5). The diagnostic sensitivity for
PDAC and the accuracy by analyzing the MSX2 expression lev-
els were much higher than those by cytological examination.
The diagnostic sensitivity or accuracy by the evaluation of MSX2
expression compared favorably to other markers such as telom-
erase (Ohuchida et al., 2005) or MUC1 (Wang et al., 2007) and
is similar to the combination analysis of the DNA concentra-
tion of methylated cyclin D2, NPTX2, and TFPI2 promoter in
brush cytological samples (Parsi et al., 2008). Although the K-
ras mutation was reported to be more frequently found in brush
samples (Van Laethem et al., 1995; Pugliese et al., 2001), it is
difficult to use the the K-ras mutation as a tool to differentiate
PDAC from CP since this mutation is also frequently detected in
CP (Yanagisawa et al., 1993). For example, the K-ras mutation
was frequently detected in both cancer (87%) and pancreatitis
(40%) when brush samples from 34 cases of PDAC and 11 of
CP were analyzed (Pugliese et al., 2001). In this context, the eval-
uation of the MSX2 expression level could be a useful tool for
differentiating PDAC from CP when a stricture is found in the
pancreatic duct.
CONCLUSION
Recent studies have clarified the functions of MSX2 in pancre-
atic tumor development. MSX2 appears to enhance the malignant
phenotype of PDAC by stimulating cell proliferation, the induc-
tion of EMT and an increase in the characteristics of CSCs
(Figure 1). MSX2 also plays an important role in enhancing
the aggressiveness of BD-IPMN, indicating that this gene may
be a good therapeutic target in pancreatic tumors. Moreover,
measurement of the MSX2 expression level in endoscopic brush
FIGURE 1 | Summary of the roles of MSX2 in pancreatic tumor development.
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samples enabled the differentiation of malignant strictures in the
pancreatic duct from benign ones, suggesting that the evaluation
ofMSX2 could be applied clinically for the diagnosis of malignant
pancreatic tumor.
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